Advertisement

Phosphate-Restricted Diets versus Calcitonin in the Prevention of Osteodystrophy in Experimental Renal Disease

  • Angela D’Angelo
  • Ermanno Bonucci
  • Paola Ballanti
  • Antonia Fabris
  • Sandro Giannini
  • Paolo Ferrarese
  • Paolo Vassanelli
  • Giuseppe Maschio
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 178)

Abstract

Restriction of dietary phosphate intake is beneficial in preventing the development of secondary hyperparathyroidism and bone disease in experimental renal failure in the dog (l–3). If associated with vitamin D administration, this dietary regimen can prevent both pathologic bone resorption and osteomalacia in the same experimental model (3). In rats with surgically-induced renal failure, the administration of phosphate-deficient diets (0.03% phosphate) is followed by anorexia, hypophosphatemia, growth arrest, stunting, and severe rickets (4,5). On the other hand, growth failure is also commonly observed when the same animals are given high-phosphate diets (1.58 % phosphate) (6).

Keywords

Phosphate Intake Salmon Calcitonin Renal Osteodystrophy Renal Bone Disease Experimental Renal Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    SLATOPOLSKY E., CAGLAR S., PENNELL J.P., TAGGART D.D., CANTERBURY J. M., REISS E., BRICKER N.S.: On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J.Clin.Invest. 50, 422–499, 1971.CrossRefGoogle Scholar
  2. 2).
    SLATOPOLSKY E., CAGLAR S., GRADOWSKA L., CANTERBURY J., REISS E., BRICKER N.S.: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intake. Kidney Intern. 2, 147151, 1972.Google Scholar
  3. 3).
    RUTHERFORD W.E., BORDIER P., MARIE P., HRUSKA K., HARTER H., GREENWALT A., BLONDIN J., HADDAD J., BRICKER N., SLATOPOLSKY E.: Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J.Clin. Invest. 60, 332–341, 1977.CrossRefGoogle Scholar
  4. 4).
    SALUSKY I., KLEINKNECHT C., BROYER M., GUBLER M.-C.: Prolonged renal survival and stunting with protein-deficient diets in experimental uremia. J.Lab.Clin.Med. 97, 21–30, 1981.PubMedGoogle Scholar
  5. 5).
    LAOUARI D., KLEINKNECHT C., COURNOT-WITMER G., HABIB R., BROYER M.: Importance of anorexia in the preservation of renal function due to deficient phosphorus diets. Third Intern.Congr.Nutrition and Metabolism in Renal Disease,Abstract Book,n. 89, 1982.Google Scholar
  6. 6).
    KLEINKNECHT C., SALUSKY I., BROYER M., GUBLER M.-C.: Effect of various protein diets on growth, renal function, and survival of uremic rats. Kidney Intern. 15, 534–541, 1979.CrossRefGoogle Scholar
  7. 7).
    FELETTI C., DOCCI D., CAPELLI M., BONOMINI V.: Pathophysiology of endogenous calcitonin in chronic uremia. Min.Electrol.Metab. 6, 174–181, 1981.Google Scholar
  8. 8).
    HEYNEN G., KANIS J.A., OLIVER D., LEDINGHAM J.G.G., RUSSELL R.G.G.: Evidence that endogenous calcitonin protects against renal bone disease. Lancet 2, 1322–1326, 1976.CrossRefGoogle Scholar
  9. 9).
    KANIS J.A., EARNSSHAW M., HEYNEN J., RUSSELL R.G.G., WOODS C.G.:The possible role of calcitonin deficiency in the development of bone disease due to chronic renal failure. Calcif.Tissue Res. 22, 147–153, 1977.PubMedCrossRefGoogle Scholar
  10. 10).
    HABENER F., SCHILLER A.L.: Pathogenesis of renal osteodystrophy: a role for calcitonin ? New Engl.J.Med. 296, 1112–1113, 1977.PubMedCrossRefGoogle Scholar
  11. 11).
    FELETTI C., BONOMINI V.: Effect of calcitonin on bone lesions in chronic dialysis patients. Nephron 24, 85–88, 1979.PubMedCrossRefGoogle Scholar
  12. 12).
    FARRINGTON K., VARGHESE Z., MOORHEAD J.F.: Human calcitonin in the treatment of renal osteodystrophy. J.Labor.Clin.Med. 96, 299–306, 1980.Google Scholar
  13. 13).
    CUNDY T., KANIS J.A., HEYNEN G., PATON S., EARNSHAW M., WOODS C.G.: Deterioration of renal bone disease in patients treated with salmon calcitonin. Clin.Endocrinol. 16, 29–37, 1982.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Angela D’Angelo
    • 1
    • 2
    • 3
    • 4
  • Ermanno Bonucci
    • 1
    • 2
    • 3
    • 4
  • Paola Ballanti
    • 1
    • 2
    • 3
    • 4
  • Antonia Fabris
    • 1
    • 2
    • 3
    • 4
  • Sandro Giannini
    • 1
    • 2
    • 3
    • 4
  • Paolo Ferrarese
    • 1
    • 2
    • 3
    • 4
  • Paolo Vassanelli
    • 1
    • 2
    • 3
    • 4
  • Giuseppe Maschio
    • 1
    • 2
    • 3
    • 4
  1. 1.I Clinica MedicaUniversitá di PadovaItaly
  2. 2.V Cattedra Anatomia PatologicaUniversitá di RomaItaly
  3. 3.Cattedra Nefrologia MedicaUniversitá di VeronaItaly
  4. 4.Cattedra Chirurgia SperimentaleUniversitá di PadovaItaly

Personalised recommendations